U.S. stock market midday update: HCW Biologics up 38.62% with trading volume surging, facing both overbought risks and momentum pressure!

U.S. Stock Market Midday Update HCW Biologics rose 38.62%, with increased trading volume. Based on recent key news: On May 18, HCW Biologics' RSI reached 82.75, indicating an overbought condition, and the stock price is likely to experience a pullback and profit-taking after a rapid rise. According to Benzinga Pro data, HCW Biologics' stock price fell 19.09% in pre-market trading on Monday, to $0.98. On May 19, momentum risk became a major focus, with the RSI reaching 84.20, indicating that the stock price is overbought and more likely to experience a pullback or consolidation. In the long term, the moving average structure remains bearish, with the 20-day moving average below the 50-day moving average, and the 50-day moving average below the 200-day moving average. According to Benzinga Pro data, HCW Biologics' stock price fell 17.16% upon release on Tuesday, to $1.12. Recent trading volume has significantly increased, indicating high market attention and trading activity for this stock. The market momentum risk has increased, requiring cautious observation. Top Stocks by Trading Volume in the Industry Amgen fell 0.43%, with increased trading volume. Based on recent key news: On May 19, Amgen announced the retirement of Chief Financial Officer Peter Griffith, with Thomas Dittrich set to succeed him. This news has raised market concerns about changes in the company's management, which may affect investor confidence. On May 20, Amgen performed steadily in the biotechnology sector, with a slight increase in stock price of 1.96%. Market recognition of its R&D investments and strategic partnerships has driven the stock price up. On May 20, analysts held a buy view on Amgen's technical signals, combined with recent stock price performance, indicating improved market expectations. The biotechnology industry is innovation-driven, with high market volatility risk. Immunovant rose 25.02%. Based on recent key news: On May 20, Immunovant announced the potential of its IMVT-1402 in various autoimmune diseases, with the market full of expectations for its future commercialization prospects, driving the stock price up. The company has cash reserves of approximately $902.1 million to support the potential commercialization of IMVT-1402. Source: MT Newswires On May 20, Immunovant reported a net loss of $0.73 per share for the fourth quarter, exceeding analysts' expected loss of $0.59 per share. Despite poor financial performance, market confidence in its new drug development remains strong. Source: Reuters On May 20, analysts rated Immunovant as "buy," predicting that its stock price will reach $42 within the next 12 months, indicating significant upside potential from the current price. Source: Reuters The biotechnology industry has recently performed strongly, with noticeable capital inflows Silexion Therapeutics rose by 114.57%. Based on recent key news: On May 20, Silexion Therapeutics announced the exercise of warrants, generating a total revenue of $1 million. This news boosted market confidence and significantly drove up the stock price. No other significant news recently. No other significant news recently. Trading volume increased, and capital inflow was evident. Stocks ranked at the top of the industry market capitalization AbbVie fell by 0.19%. Based on recent key news: On May 19, Belgian biopharmaceutical company UCB announced Phase III study data for its IL-17A/IL-17F inhibitor Bimzelx, showing it outperformed AbbVie's Skyrizi in treating psoriatic arthritis. This result raised market concerns about AbbVie's product competitiveness, affecting its stock price. On May 20, Rongchang Biologics announced a collaboration agreement with AbbVie, licensing its PD-1/VEGF dual antibody RC148, with an upfront payment of $650 million. This collaboration provided significant liquidity support for Rongchang Biologics but failed to significantly boost AbbVie's stock price. On May 18, MarketBeat reported that although AbbVie received a moderate buy rating from analysts, it was not listed among the top five recommended stocks for purchase, affecting investor confidence. Competition in the pharmaceutical industry is intensifying, with a focus on innovative drugs